Piper Sandler Raises Price Target for Biogen (BIIB) to $177 | BI

Piper Sandler has reiterated a Neutral rating on Biogen (BIIB) and increased its price target from $157 to $177, reflecting a 12.74% raise. This adjustment follows a trend of several analysts raising their price targets for Biogen, indicating a generally more optimistic outlook on the company’s valuation. Biogen, a biopharmaceutical company focusing on neurological and rare diseases, has an average target price of $200.49 from 30 analysts, suggesting a slight downside from its current share price.